KEY POINTS
- This retrospective single-institution study from Masaryk Memorial Cancer Institute, Czech Republic, included 115 consecutive patients treated with SBRT for peripheral pulmonary lesions between January 2011 and January 2024. Median age was 75 years, 90% were medically inoperable, and lesions were limited to ≤50 mm. Histological confirmation was available in 79 patients (69%), while the remaining 36 were treated based on radiological findings and multidisciplinary assessment. Right-sided lesions accounted for 66 patients (57%) and left-sided lesions for 49 (43%).
- Ablative SBRT was delivered using risk-adapted fractionation and daily image guidance. The most common schedules were 42–54 Gy in three fractions (53%), 50–55 Gy in five fractions (35%), and 60 Gy in eight fractions (12%), with median prescribed BED10 of 116 Gy (range 100–151 Gy). Treatment used 4DCT-based motion assessment, respiratory gating or deep inspiration breath-hold when appropriate, 3–5 mm PTV margins, VMAT, and pretreatment CBCT verification.
- Long-term local control was favorable despite substantial competing mortality. At a median follow-up of 39 months, the cumulative incidence of local recurrence was 2.3% at two years and 7.1% at five years. Five-year locoregional recurrence and distant metastasis incidences were 16% and 41%, respectively. Median overall survival was 64.3 months, with 55% five-year overall survival and 39% five-year progression-free survival.
- Left-sided tumor location was associated with substantially worse survival. Five-year overall survival was 36% for left-sided versus 70% for right-sided lesions, corresponding to a cause-specific comparison for mortality of HR 2.96 (95% CI 1.59–5.50; p<0.001). Five-year progression-free survival was 18% versus 58%, respectively, with HR 3.30 (95% CI 1.86–5.86; p<0.001). Median overall survival was 33.0 months for left-sided versus 82.7 months for right-sided tumors.
- Locoregional recurrence and cancer-specific mortality also differed by laterality. Five-year cumulative locoregional recurrence was 23% for left-sided versus 7.5% for right-sided lesions, with HR 3.60 (95% CI 1.25–10.4; p=0.015). Five-year cancer-specific death incidence was 34% versus 8.5%, with HR 3.96 (95% CI 1.53–10.2; p=0.003). In contrast, the associations with isolated local recurrence (HR 3.67; p=0.106) and distant metastasis (HR 1.91; p=0.062) were not statistically significant.
- Treatment-related toxicity was limited in the reported cohort. Chest wall pain, rib fractures, pneumonitis, or esophagitis occurred in 15/115 patients (13%), with all recorded complications classified as grade 1–2 and transient. No grade ≥3 treatment-related toxicity was reported. The dose and fractionation distributions did not differ significantly between laterality groups, and no significant associations between conventional target-dose parameters and clinical outcomes were identified.
- The laterality findings remain hypothesis-generating despite exploratory adjustment. Associations with overall survival, progression-free survival, locoregional recurrence, and cancer-specific death persisted after adjustment for selected covariates, but left-sided patients had a greater numerical burden of comorbidity (86% vs 68% with more than three comorbidities). The study included only 17 locoregional recurrence events and 21 cancer-specific deaths, while 31% of lesions lacked pathological confirmation. Crucially, cardiac dose parameters were unavailable, preventing evaluation of whether differential heart exposure contributed to the observed survival differences.
CLINICAL TAKEAWAY
SBRT achieved favorable local control with limited reported toxicity in medically inoperable patients with peripheral pulmonary lesions. The substantially worse survival observed with left-sided disease warrants further investigation, but the retrospective design, small number of events, and absence of cardiac dosimetry do not justify treating tumor laterality as an established independent prognostic factor or changing SBRT planning solely on this basis.